Understanding ANPEP: Potential Drug Target and Biomarker (G290)

Target Name: ANPEP

NCBI ID: G290

ANPEP

Understanding ANPEP: Potential Drug Target and Biomarker

ANPEP (Microsomal aminopeptidase) is a protein that is expressed in the mitochondria and is involved in the metabolism of amino acids. It is a 26 kDa protein that consists of two distinct subunits, alpha-subunit (AS) and beta-subunit (BS). The AS subunit is responsible for the catalytic activity, while the BS subunit plays a structural role.

ANPEP is involved in the catabolism of a variety of amino acids, including alanine, aspartic acid, glutamic acid, and cysteine. It is a potent enzyme that converts these amino acids to their respective carbon amino acids, which are then excreted from the body.

ANPEP is a potential drug target for several reasons. Firstly, ANPEP is a highly conserved protein, which suggests that it is a good candidate for drug targeting. Secondly, it is involved in the metabolism of essential amino acids, which makes it an attractive target for drugs that are aimed at treating amino acid deficiencies. Additionally, ANPEP is located in the mitochondria, which are known to play a role in the regulation of energy metabolism and is thought to be involved in the detoxification of harmful substances.

AS and BS subunits of ANPEP have been shown to interact with various drug molecules, including small molecules, peptides, and proteins. The AS subunit has been shown to interact with various small molecules, including inhibitors of the enzyme Parkinase, which is involved in the catabolism of amino acids. The BS subunit has been shown to interact with the protein tyrosine phosphatase (PTP) in response to various treatments, including inhibitors of the enzyme Pyroptidase.

In addition to its potential as a drug target, ANPEP is also a potential biomarker for certain diseases. For example, ANPEP has been shown to be decreased in individuals with Alzheimer's disease, which suggests that it may be a potential diagnostic biomarker for this disease. Additionally, ANPEP has been shown to be decreased in individuals with cancer, which may indicate that it is a potential therapeutic target for cancer.

Despite the potential benefits of ANPEP as a drug target and biomarker, more research is needed to fully understand its role in the regulation of amino acid metabolism and its potential clinical applications. ANPEP is a complex protein that is involved in a variety of cellular processes, and further studies are needed to fully understand its role in these processes. Additionally, more research is needed to determine the efficacy and safety of ANPEP as a potential drug target and biomarker.

In conclusion, ANPEP is a protein that is expressed in the mitochondria and involved in the metabolism of amino acids. It is a highly conserved protein that is involved in the catabolism of essential amino acids, making it an attractive candidate for drug targeting. Additionally, ANPEP is located in the mitochondria, which are involved in the regulation of energy metabolism and is thought to be involved in the detoxification of harmful substances. Further research is needed to fully understand the role of ANPEP in these processes and its potential clinical applications.

Protein Name: Alanyl Aminopeptidase, Membrane

Functions: Broad specificity aminopeptidase which plays a role in the final digestion of peptides generated from hydrolysis of proteins by gastric and pancreatic proteases. Also involved in the processing of various peptides including peptide hormones, such as angiotensin III and IV, neuropeptides, and chemokines. May also be involved the cleavage of peptides bound to major histocompatibility complex class II molecules of antigen presenting cells. May have a role in angiogenesis and promote cholesterol crystallization. May have a role in amino acid transport by acting as binding partner of amino acid transporter SLC6A19 and regulating its activity (By similarity)

The "ANPEP Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ANPEP comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets